Job Description
About This Role
Biogens Gene Therapy Accelerator Unit is driving innovation on both technology and drug discovery process fronts to accelerate gene therapies that may one day help transform the way we treat neurological diseases. We are looking for an innovative, enthusiastic, and dedicated scientist to join our team and contribute to the generation of pioneering gene therapies.
You will work independently and with cross-functional teams to support Biogens pre-clinical pipeline and technology innovation programs with AAV vectors for in vivo and in vitro use.
What Youll Do
* Support the production of AAV in adherent and suspension mammalian systems
* Execute validated protocols for the purification of AAV preps (ultracentrifugation or chromatography based) and perform characterization using standard molecular biology and biochemistry techniques
* Support process development for the refinement of the existing upstream and downstream SOPs
* Manage CROs for external AAV vector production
* Maintain accurate laboratory records, present data to the team, and co-author internal reports and scientific communications
Who You Are
You are passionate about gene therapy research and use your scientific curiosity to drive novel discoveries. You are a forward-thinker, motivated to learn new skills, and are a team player who strives to make an impact on patients lives.
LI-SK1
Qualifications
Required Skills
* MS or BS in biology, biochemistry, biotechnology, or related field
* Associate Scientist III: 2+ years of industry experience
* Senior Associate Scientist: 4+ years of industry experience
* Proven experience with AAV production and purification
* Strong proficiency with general molecular biology and biochemistry techniques, including, but not limited to cloning, PCR, qPCR, ddPCR, RNA analysis, Western Blot, ELISA
* Extensive experience with bench-scale AAV or recombinant protein production in adherent mammalian cells
* Design, execute, and analyze in vitro experiments independently with strong scientific rigor
* Maintain up-to-date knowledge of pertinent literature
* Possess excellent communication and interpersonal skills to efficiently collaborate and present results to project teams
Preferred Skills
* Experience with AAV/recombinant protein production in adherent/suspension cell lines at bench- and/or mid-size scale
* Hands-on experience with chromatography and/or AKTA systems
* Previous experience with rAAV or other gene therapy delivery system as a therapeutic tool for neuroscience/neurological disorders
Why Biogen?
Our mission to find therapies for neurological and rare diseases is a unique focus within our industry and this shared purpose is what connects us as a team. We work together to overcome obstacles and to follow the science. We are resilient as we strive to make an impact on our patients lives and on changing the course of medicine. Together, we pioneer. Together, we thrive.
Additional Information
Biogen is strengthening its commitment to becoming the leaders in neuroscience gene therapy and we are looking for the next great scientific minds in this area of research.
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.